Literature DB >> 2295817

A monoclonal antibody to VLA-4 alpha-chain (CDw49d) induces homotypic lymphocyte aggregation.

J L Bednarczyk1, B W McIntyre.   

Abstract

The complex processes of cellular adhesion involve a variety of receptor to ligand interactions that are extremely important during the development of immune function. Lymphocyte activation by Ag or mitogen, CTL- and NK-mediated cytolysis, homing to lymphoid-associated tissue, and the attachment of lymphocytes to extracellular matrix proteins are all governed, at least in part, by cell surface adhesion receptors. During the analysis of mAb for the ability to block human cytotoxic T lymphocyte-mediated killing an inhibitory mAb was noted that caused rapid and vigorous aggregation among the CTL. This antibody, mAb L25, also induced aggregation among human T and B tumor cell lines. mAb L25 binds to an epitope on the alpha 4 subunit of the integrin protein VLA-4 and induced an adhesion event requiring divalent cations, energy, a fluid plasma membrane, and an intact cytoskeleton. The Ag-independent homotypic adhesion induced by mAb L25 was not inhibited by mAb to the lymphocyte function associated Ag-1 (CD11a/CD18), CD2, CD4, and CD8, or to their ligands ICAM-1, LFA-3, MHC class I, or MHC class II. We believe that these experiments suggest a role for VLA-4 in a novel system of leukocyte adhesion.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2295817

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

1.  Cell-surface regulation of beta 1-integrin activity on developing retinal neurons.

Authors:  K M Neugebauer; L F Reichardt
Journal:  Nature       Date:  1991-03-07       Impact factor: 49.962

2.  Anti-alpha 4 integrin antibody induces apoptosis in murine thymocytes and staphylococcal enterotoxin B-activated lymph node T cells.

Authors:  E Z Tchilian; J J Owen; E J Jenkinson
Journal:  Immunology       Date:  1997-11       Impact factor: 7.397

3.  Changes in gravity inhibit lymphocyte locomotion through type I collagen.

Authors:  N R Pellis; T J Goodwin; D Risin; B W McIntyre; R P Pizzini; D Cooper; T L Baker; G F Spaulding
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-05       Impact factor: 2.416

4.  A model for the kinetics of homotypic cellular aggregation under static conditions.

Authors:  S Neelamegham; L L Munn; K Zygourakis
Journal:  Biophys J       Date:  1997-01       Impact factor: 4.033

5.  Homotypic aggregation of murine T lymphocytes induced by anti-Thy-1 monoclonal antibodies.

Authors:  K Isobe; I Nakashima
Journal:  Immunology       Date:  1991-06       Impact factor: 7.397

6.  Specific cleavage of the alpha 4 integrin associated with activation of peripheral T lymphocytes.

Authors:  M L Blue; G Davis; P Conrad; K Kelley
Journal:  Immunology       Date:  1993-01       Impact factor: 7.397

7.  Integrins as a primary signal transduction molecule regulating monocyte immediate-early gene induction.

Authors:  A D Yurochko; D Y Liu; D Eierman; S Haskill
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

8.  Expression and ligand-binding function of the integrin alpha 4 beta 1 (VLA-4) on neural-crest-derived tumor cell lines.

Authors:  J L Bednarczyk; B W McIntyre
Journal:  Clin Exp Metastasis       Date:  1992-07       Impact factor: 5.150

9.  VLA family in rheumatoid arthritis: evidence for in vivo regulated adhesion of synovial fluid T cells to fibronectin through VLA-5 integrin.

Authors:  R García-Vicuña; A Humbría; A A Postigo; C López-Elzaurdia; M O de Landázuri; F Sánchez-Madrid; A Laffón
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

10.  Increased binding of synovial T lymphocytes from rheumatoid arthritis to endothelial-leukocyte adhesion molecule-1 (ELAM-1) and vascular cell adhesion molecule-1 (VCAM-1).

Authors:  A A Postigo; R Garcia-Vicuña; F Diaz-Gonzalez; A G Arroyo; M O De Landázuri; G Chi-Rosso; R R Lobb; A Laffon; F Sánchez-Madrid
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.